| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology and Physiology, University of New Mexico School of Medicine, and the Neurology Service, Veterans Health Administration Medical Center, Albuquerque, NM.
Supported by a grant to the University of New Mexico for the Clinical Research Center (NIH: NCRR, 5M01 RR00997-18). Other support came from NIH (RO1 NS21169-07) and the VA Research Service to GR.
Received August 15, 1995. Accepted in final form October 12, 1995.
Address correspondence and reprint requests to Dr. Gary A. Rosenberg, Department of Neurology, University of New Mexico, Albuquerque, NM 87131.
Contrast-enhanced MRI in patients with MS shows that increased permeability of the blood-brain barrier (BBB) commonly occurs. The changes in capillary permeability often precede T2-weighted MRI evidence of tissue damage. In animal studies, intracerebral injection of the matrix metalloproteinase (MMP) 72-kDa type IV collagenase (gelatinase A) opens the BBB by disrupting the basal lamina around capillaries. Steroids affect production of endogenous MMPs and tissue inhibitors to metalloproteinases (TIMPs). To determine the role of MMP activity in BBB damage during acute exacerbations of MS, we measured MMPs in the CSF of patients with MS. Patients (n = 7) given steroids to treat an acute episode of MS had CSF sampled before and after 3 days of methylprednisolone (1 g/day). Patients had a graded neurologic examination and gadolinium-enhanced MRI before treatment. CSF studies included total protein, cell count, and a demyelinating profile. We measured levels of MMPs, urokinase-type plasminogen activator (uPA), and TIMPs by zymography, reverse zymography, and Western blots. The MMP, 92-kDa type IV collagenase (gelatinase B), fell from 216 +/- 70 before steroids to 54 +/- 26 relative lysis zone units (p < 0.046) after treatment. Similarly, uPA dropped from 3880 +/- 800 to 2655 +/- 353 (p < 0.03). Four patients with gadolinium enhancement on MRI had the most pronounced drop in gelatinase B and uPA. Western immunoblots showed an increase in a complex of gelatinase B and TIMPs after treatment, suggesting an increase in a TIMP (p < 0.05). Reverse zymography of CSF samples showed that steroids increased a TIMP with a molecular weight similar to that of mouse TIMP-3 (p = 0.053). Our results suggest that increased gelatinase B is associated with an open BBB on MRI. Steroids may improve capillary function by reducing activity of gelatinase B and uPA and increasing levels of TIMPs.
NEUROLOGY 1996;46: 1626-1632
This article has been cited by other articles:
|
|
 |
|
  J. K. Olson and S. D. Miller The Innate Immune Response Affects the Development of the Autoimmune Response in Theiler's Virus-Induced Demyelinating Disease J. Immunol., May 1, 2009; 182(9): 5712 - 5722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Tsai, L.-Y. Chung, E.-R. Chen, Y.-C. Liu, S. S.-J. Lee, Y.-S. Chen, C.-L. Sy, S.-R. Wann, and C.-M. Yen Association of Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-4 in Cerebrospinal Fluid with Blood-Brain Barrier Dysfunction in Patients with Eosinophilic Meningitis Caused by Angiostrongylus cantonensis Am J Trop Med Hyg, January 1, 2008; 78(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Forster, T. Kahles, S. Kietz, and D. Drenckhahn Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND J. Physiol., May 1, 2007; 580(3): 937 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. C. Hsu, R. McKeon, S. Goussev, Z. Werb, J.-U. Lee, A. Trivedi, and L. J. Noble-Haeusslein Matrix Metalloproteinase-2 Facilitates Wound Healing Events That Promote Functional Recovery after Spinal Cord Injury J. Neurosci., September 27, 2006; 26(39): 9841 - 9850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Avolio, M Filippi, C Tortorella, M A Rocca, M Ruggieri, F Agosta, V Tomassini, C Pozzilli, S Stecchi, P Giaquinto, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment Multiple Sclerosis, August 1, 2005; 11(4): 441 - 446. [Abstract] [PDF]
|
|
|
|
|
|
J Sastre-Garriga, M Comabella, L Brieva, A Rovira, M Tintore, and X Montalban Decreased MMP-9 production in primary progressive multiple sclerosis patients Multiple Sclerosis, August 1, 2004; 10(4): 376 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, and D. Leppert IFN{beta} lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS Neurology, January 14, 2003; 60(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Rosenberg Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis Neuroscientist, December 1, 2002; 8(6): 586 - 595. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Abraham, S. Shapiro, N. Lahat, and A. Miller The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells Int. Immunol., December 1, 2002; 14(12): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Chintala, X. Zhang, J. S. Austin, and M. E. Fini Deficiency in Matrix Metalloproteinase Gelatinase B (MMP-9) Protects against Retinal Ganglion Cell Death after Optic Nerve Ligation J. Biol. Chem., November 27, 2002; 277(49): 47461 - 47468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Ozenci, M Kouwenhoven, and H Link Cytokines in multiple sclerosis: methodological aspects and pathogenic implications Multiple Sclerosis, October 1, 2002; 8(5): 396 - 404. [Abstract] [PDF]
|
|
|
|
|
|
V. W. Yong Differential mechanisms of action of interferon-{beta} and glatiramer acetate in MS Neurology, September 24, 2002; 59(6): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, H.F. McFarland, and J. A. Frank Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN{beta}-1b Neurology, September 10, 2002; 59(5): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Noble, F. Donovan, T. Igarashi, S. Goussev, and Z. Werb Matrix Metalloproteinases Limit Functional Recovery after Spinal Cord Injury by Modulation of Early Vascular Events J. Neurosci., September 1, 2002; 22(17): 7526 - 7535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gelati, E. Corsini, M. De Rossi, L. Masini, G. Bernardi, G. Massa, A. Boiardi, and A. Salmaggi Methylprednisolone Acts on Peripheral Blood Mononuclear Cells and Endothelium in Inhibiting Migration Phenomena in Patients With Multiple Sclerosis Arch Neurol, May 1, 2002; 59(5): 774 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gveric, R. Hanemaaijer, J. Newcombe, N. A. van Lent, C. F. M. Sier, and M. L. Cuzner Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage Brain, October 1, 2001; 124(10): 1978 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Price, J. Farrar, T. T. H. Chau, N. T. H. Mai, T. T. Hien, and J. S. Friedland Identification of a Matrix-Degrading Phenotype in Human Tuberculosis In Vitro and In Vivo J. Immunol., March 15, 2001; 166(6): 4223 - 4230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Michel, R. Zobotke, M. Mader, and R. Nau Regulation of Matrix Metalloproteinase Expression in Endothelial Cells by Heat-Inactivated Streptococcus pneumoniae Infect. Immun., March 1, 2001; 69(3): 1914 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Mandler, J. D. Dencoff, F. Midani, C. C. Ford, W. Ahmed, and G. A. Rosenberg Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica Brain, March 1, 2001; 124(3): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N D Richert, J L Ostuni, C N Bash, T P Leist, H F McFarland, and J A Frank Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis Multiple Sclerosis, February 1, 2001; 7(1): 49 - 58. [Abstract] [PDF]
|
|
|
|
|
|
B. C. Kieseier, C. Schneider, J. M. Clements, A. J. H. Gearing, R. Gold, K. V. Toyka, and H.-P. Hartung Expression of specific matrix metalloproteinases in inflammatory myopathies Brain, February 1, 2001; 124(2): 341 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Harkness, P. Adamson, J. D. Sussman, G. A. B. Davies-Jones, J. Greenwood, and M. N. Woodroofe Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium Brain, April 1, 2000; 123(4): 698 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Giraudon, R. Szymocha, S. Buart, A. Bernard, L. Cartier, M.-F. Belin, and H. Akaoka T Lymphocytes Activated by Persistent Viral Infection Differentially Modify the Expression of Metalloproteinases and Their Endogenous Inhibitors, TIMPs, in Human Astrocytes: Relevance to HTLV-I-Induced Neurological Disease J. Immunol., March 1, 2000; 164(5): 2718 - 2727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gasperini, C. Pozzilli, S. Bastianello, E. Giugni, M. A Horsfield, T. Koudriavtseva, S. Galgani, A. Paolillo, S. Haggiag, E. Millefiorini, et al. Interferon-beta -1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images J. Neurol. Neurosurg. Psychiatry, November 1, 1999; 67(5): 579 - 584. [Abstract] [Full Text]
|
|
|
|
|
|
C. T. Bever Jr. and G. A. Rosenberg Matrix metalloproteinases in multiple sclerosis Neurology, October 22, 1999; 53(7): 1380 - 1380. [Full Text] [PDF]
|
|
|
|
|
|
E. Waubant, D. E. Goodkin, L. Gee, P. Bacchetti, R. Sloan, T. Stewart, P.-B. Andersson, G. Stabler, and K. Miller Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis Neurology, October 22, 1999; 53(7): 1397 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trojano, C. Avolio, G. M. Liuzzi, M. Ruggieri, G. Defazio, M. Liguori, M. P. Santacroce, D. Paolicelli, F. Giuliani, P. Riccio, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFN{beta}-1b treatment in relapsing-remitting MS Neurology, October 22, 1999; 53(7): 1402 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, R. Paul, U. Koedel, T. Seifert, J. M. Clements, A. J. H. Gearing, H.-W. Pfister, and H.-P. Hartung Differential expression of matrix metalloproteinases in bacterial meningitis Brain, August 1, 1999; 122(8): 1579 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, T. Seifert, G. Giovannoni, and H.-P. Hartung Matrix metalloproteinases in inflammatory demyelination: Targets for treatment Neurology, July 1, 1999; 53(1): 20 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
D. Leppert, P. Hughes, S. Huber, B. Erne, C. Grygar, G. Said, K. M. Miller, A. J. Steck, A. Probst, and P. Fuhr Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy Neurology, July 1, 1999; 53(1): 62 - 62. [Abstract] [Full Text]
|
|
|
|
|
|
P. F Smith and C. L Darlington Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Lee, J. Palace, G. Stabler, J. Ford, A. Gearing, and K. Miller Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: A longitudinal clinical and MRI study Brain, February 1, 1999; 122(2): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
